3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Hodgkin Disease
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Gastrointestinal Stromal Tumors
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Interventions
Rituximab
101
Cyclophosphamide
51
Prednisone
32
Doxorubicin
32
Vincristine
31
Gemcitabine
29
Lenalidomide
27
Oxaliplatin
22
Bendamustine Hydrochloride
19
ibrutinib
16
fludarabine
16
tafasitamab
12
polatuzumab vedotin
12
venetoclax
11
tisagenlecleucel
11
obinutuzumab
11
loncastuximab tesirine
9
Etoposide
9
zanubrutinib
8
Prednisolone
8
Injections
8
Ifosfamide
8
Carboplatin
8
selinexor
7
pembrolizumab
7
durvalumab
7
axicabtagene ciloleucel
7
Dexamethasone
7
tazemetostat
6
parsaclisib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Large B-Cell, Diffuse
×
umbralisib
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA